lunedì, 14 settembre 2026

Notizie AIOM – anno XVI n. 667

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with ...
Leggi tutto

AJCC Staging Manual Gives Boost to Precision Medicine

March 10, 2018 - The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer (AJCC) is a quantum leap toward precision oncology, as it codifies advanced knowledge of the role of biologic factors in cancer, and oncologists should ...
Leggi tutto

Apalutamide Added to NCCN Prostate Cancer Guidelines

March 12, 2018 - The NCCN now lists apalutamide as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). In treatment guidelines issued March 8, 2018, the NCCN included the next-generation androgen receptor ...
Leggi tutto

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

March 14, 2018 - Immunotherapy has taken over the conversation for oncologists when discussing treatments for patients with lung cancer, explains Heather Greene, NP. The class of agents has been generally well tolerated in this patient population; however, there are adverse ...
Leggi tutto

FDA Grants Pembrolizumab Priority Review in Cervical Cancer

March 13, 2018 - The FDA has granted a priority review to pembrolizumab for the treatment of advanced cervical cancer with disease progression on or after chemotherapy. The agency has set a PDUFA date of June 28, 2018. Merck, the developer of pembrolizumab, reported in a ...
Leggi tutto

FDA Halts Combo Trial of Axalimogene Filolisbac Plus Durvalumab

March 13, 2018 - The FDA has put a clinical hold on a phase I/II study of axalimogene filolisbac (AXAL) plus durvalumab for the treatment of patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck squamous cell carcinoma ...
Leggi tutto

Symptom Burden in the First Year After Cancer Diagnosis: An Analysis of Patient-Reported Outcomes

Improvement in the quality of life of patients with cancer requires attention to symptom burden across the continuum of care, with the use of patient-reported outcomes key to achieving optimal care. Yet there have been few studies that have examined symptoms in the early ...
Leggi tutto

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future ...
Leggi tutto

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether patients with low-volume (LV) disease benefit from early ...
Leggi tutto

13 marzo 2018 – Registri AIFA: l’Agenzia fornisce informazioni sui dati dei trattamenti con i nuovi farmaci per la cura dell’epatite C